Delcath Systems, Inc. announced that patient treatment and data collection for the intrahepatic cholangiocarcinoma (ICC) cohort of its European Phase 2 HCC/ICC study is ongoing, and that the company will announce interim results for the cohort once the data are fully mature. Additionally, the Company believes that the original goal to obtain an efficacy signal for the Phase 2 ICC cohort has been satisfied by the result of multicenter patient outcomes identified in the retrospective data collection of commercial ICC cases conducted by European investigators. These promising outcomes and observations were discussed with Key Opinion Leaders (KOL) at a Delcath-organized medical advisory panel meeting and led to the agreement that PHP® therapy does, indeed, "demonstrate an efficacy signal in ICC and is worthy of full clinical investigation. The company also announces that it has accepted an invitation from The Cholangiocarcinoma Foundation (CCF) to present its initial research plans for use of PHP® therapy in the treatment ICC. The CCF is the large patient advocacy organization devoted to finding a cure and improving the quality of life for patients with cholangiocarcinoma, or bile duct cancers.